慢性肾脏病患者甲状旁腺增生机制研究新进展
被引量:9
摘要
继发性甲状旁腺功能亢进(secondary hyper-parathyroidismSHPT)是慢性肾脏病(chronic kid-neydisease,CKD)患者钙磷代谢紊乱和维生素D作用减退进行性加重的适应性反应,其特征是甲状旁腺增牛和甲状旁腺素(parathyroid hormone PTH)过度合成和分泌,进而导致骨过度重吸收,软组织和血管钙化,
出处
《中国血液净化》
2008年第11期622-625,共4页
Chinese Journal of Blood Purification
参考文献35
-
1Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failuref[J].J Am Soc Nephrol, 2000, 11:1141-1152.
-
2Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling[J]. Physiol Rev ,2001, 81:239-297.
-
3Henley C, Davis J, Miller G, et al. Calcium gluconate increases iCa, attenuates pPTH and parathyroid (PT) hyperplasia in uremic rats without causing calcification:Ab stract 162 presented at National Kidney Foundation Spring Clinical Meeting, 19-23 April 2006: Chicago.
-
4Roussanne MC, Lieberherr M, Souberbielle JC, et al. Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate[J]. Eur J Clin Invest, 2001, 31:610-616.
-
5D'Souza-Li L, Yang B, Canaff L, et al. Identification and functional characterization of novel calcium sensing re ceptor mutations in familial hypocalciuric hypcrcalcemia and autosomal dominant hypocalcemia[J]. J Clin Endocrinol Metab. 2002. 87:1309?318.
-
6Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of pa tients with hyperparathyroidism[J]. Kidney Int, 1997, 51: 328-336.
-
7Nemeth EF, Heaton Wll, Miller M, et al. Pharmacoldynamics of the type Ⅱ calcimimetic compound cinacalcet HCI[J].J Pharmacol Exp Ther, 2004, 308:627- 635.
-
8Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism[J]. Kidney Int,2000, 58:436-445.
-
9Levi R, Ben Dov IZ, Lavi-Moshayoff V, et al. Increased parathyroid hormone gene expression in seeondacy hyperparathyroidism of experimental uremia is reversed by fication of the trans acting factoc AUF1[J].J Am Soc Nephrol ,2006, 17:107-112.
-
10Colloton M,Shatzen E,Miller G,et al.Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism[J].Kidney Int,2005, 67:467-476.
二级参考文献15
-
1杜学海.尿毒症继发性甲状旁腺功能亢进治疗进展:钙敏感受体激动剂[J].中国血液净化,2005,4(4):175-177. 被引量:4
-
2Kenneth B, Jonsson. The role of fibroblast growth factor 23 in renal disease[J]. Nephrol Dial Transplant, 2005, 20: 479-482.
-
3Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency Jn chronic kidney disease[J]. J Am Soc Nephrol, 2005,16:2205-2215.
-
4Collins MT, Lindsay JR, Jain A, et al. Fibroblast growth factor-23 is regulated by lalpha, 25-dihydroxyvitamin D [J]. J Bone Miner Res, 2005,20:1944-1950.
-
5Fukagawa M, Kazama JJ. FGF23: its role in renal bone disease[J]. Pediatr Nephrol, 2006,21:1802-1806.
-
6Westerberg PA, Linde T, Wikstrom B, et al. Regulation of fibroblast growth factor-23 in chronic kidney disease [J]. Nephrol Dial Transplant, 2007,22:3202-3207.
-
7Tortes PU, Friedlander G, MC de Vernejoul et al. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients[J].Kidney Int, 2008, 73:102- 107.
-
8Nishi H, Nii-Kono T, Nakanishi S, et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism[J]. Nephron Clin Praet, 2005, 101: c94-c99.
-
9陈旻译.血清磷水平的评价.王海燕,王梅主译,慢性肾脏病及透析的临床实践指南Ⅱ[M].第一版.北京,人民卫生出版社,2005,347-349.
-
10Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF- 23 levels predict the efficacy of calcitriol therapy in dialysis patients[J]. Kidney Int, 2005, 67: 1120-1125.
同被引文献96
-
1施翎,陈其军,包蓓艳.血液灌流联合活性维生素D冲击治疗继发性甲状旁腺功能亢进的临床观察[J].浙江中医药大学学报,2010,34(5):706-707. 被引量:5
-
2顾勇,丁峰,陈楠,梅长林,钱家麒,王笑云,史伟,侯凡凡,李学旺,王梅,谌贻璞.阿法迪三~冲击和每日治疗对血液透析患者继发性甲旁亢疗效的随机多中心对照临床研究[J].中华肾脏病杂志,2004,20(5):315-320. 被引量:23
-
3<活性维生素D的合理应用>专家协作组.活性维生素D在慢性肾脏病继发性甲旁亢中合理应用的专家共识(修订版)[J].中华肾脏病杂志,2005,21(11):698-699. 被引量:97
-
4候凡凡.中国慢性肾脏疾病患者的心血管危险:目前的现状和对策[J].中国血液净化,2005,4(12):641-642. 被引量:6
-
5杨继红,李天慧,王海涛,陈欢,吴华.活性维生素D和低钙透析液治疗血液透析患者继发性甲状旁腺功能亢进的疗效观察[J].中国血液净化,2006,5(5):242-244. 被引量:19
-
6慢性肾脏病骨代谢及其疾病的临床实践指南——指南8 慢性肾脏病患者的维生素D治疗[J].中国血液净化,2006,5(5):275-280. 被引量:12
-
7全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:714
-
8Chertow GM , Burke SK , Raggi P , et al. Sevelamer attenuates the progression of cardiovascular calcification in hemodialysis patients[J] . Kidney Int , 2002,62(4) :254.
-
9Bailie GR. Calcium and phosphorus management in chronic kidney disease: challenges and trends[J]. Health Module,2004,39(7):358.
-
10NKF-DOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J]. Am J Kidney Dis,2003,30(3) :192.
引证文献9
-
1张吉胜,陈其军,陈洁,应一樱,高文波,包蓓艳.口服活性维生素D冲击治疗终末期肾衰患者继发性甲状旁腺功能亢进的疗效[J].中国临床药学杂志,2010,19(5):288-290.
-
2李国辉,赵显国.低分子肝素钙对维持性血液透析患者继发性甲状旁腺功能亢进的影响[J].实用医学杂志,2011,27(12):2241-2243. 被引量:13
-
3王久艳.尿毒症患者远期并发症的机制与防治[J].医学理论与实践,2011,24(11):1277-1279. 被引量:3
-
4胡炀琳,张璜,万胜,付丽娜,何达,邹荣,李红波,胡韬韬,张英,熊飞.甲状旁腺切除术对尿毒症患者难治性继发性甲旁亢的疗效观察[J].临床肾脏病杂志,2013(3):114-117. 被引量:6
-
5蔡震川,李培贵,宋春燕.长期血液透析继发性甲旁亢患者骨化三醇冲击治疗的效果观察[J].西部医学,2013,25(6):918-919. 被引量:7
-
6马金贵.骨化三醇治疗血透患者继发性甲状旁腺功能亢进的疗效观察[J].中外医学研究,2014,12(30):14-16. 被引量:5
-
7肖蕊.口服活性维生素D冲击治疗终末期肾衰患者继发性甲状旁腺功能亢进的疗效观察[J].医学美学美容(中旬刊),2015,24(1):294-294. 被引量:3
-
8张家珍,邹新蓉,王小琴,韩四萍.慢性肾脏病非透析患者钙磷代谢紊乱的相关性分析[J].华南国防医学杂志,2016,30(5):312-315. 被引量:10
-
9雒云祥,路小燕,孙莉姬,刘紫娟,刘晴晴,程红颖.阿法骨化醇冲击治疗规律血液透析继发性甲状旁腺功能亢进患者的疗效观察[J].中国中西医结合急救杂志,2017,24(1):94-95. 被引量:15
二级引证文献61
-
1杜圣群.阿法骨化醇与西那卡塞联合用药在血液透析继发性甲亢患者的疗效[J].透析与人工器官,2022,33(4):4-6. 被引量:2
-
2慕海森.探讨阿法骨化醇冲击治疗规律血液透析继发性甲状旁腺功能亢进患者的疗效[J].世界最新医学信息文摘,2019,0(91):136-136. 被引量:2
-
3庄乙君,覃学,高海娥.不同透析方式治疗尿毒症皮肤瘙痒的疗效比较及对血清甲状旁腺素、β2微球蛋白水平的影响[J].中国老年学杂志,2014,34(4):934-936. 被引量:36
-
4钱志远.音响缩词详解——AC—3和AAC[J].高保真音响,2000(3):27-29.
-
5张建荣,李小萍,张艳霞.血液灌流改善继发性甲旁亢患者微炎症状态的临床研究[J].第三军医大学学报,2012,34(17):1786-1789. 被引量:10
-
6周福荣,王华,梁国君.继发性(肾性)甲状旁腺功能亢进的治疗研究[J].四川医学,2012,33(8):1406-1408. 被引量:7
-
7包国豪,陈法东,张疆,黄艳,陈建胜,缪初升.高通量血液透析和阿法骨化醇冲击治疗对血液透析患者继发性甲状旁腺功能亢进的疗效研究[J].实用药物与临床,2013,16(6):480-482. 被引量:5
-
8刘俊锋,付利军,李洪婷,李建华,张腾艺,邱新光.继发性甲状旁腺功能亢进的诊治[J].河南医学研究,2014,23(2):140-143. 被引量:11
-
9袁婷婷,温大翠.甲状旁腺切除加自体移植术治疗维持性透析病人继发甲状旁腺功能亢进症的护理[J].全科护理,2014,12(12):1112-1113. 被引量:1
-
10张莹.不同血液净化方式清除维持性血液透析患者高磷血症的临床对比研究[J].医学综述,2014,20(16):3062-3064. 被引量:16
-
1吴建辉,孙祖越,等.Beagle犬前列腺增生模型中增生机制发生的分子生物学研究[J].中国药理通讯,2003,20(1):74-74.
-
2王娟.烧伤后瘢痕增生机制研究进展[J].健康之路,2016,0(2):15-15.
-
3程祝忠,陈君辉,文华长,许国辉.前列腺增生的动脉栓塞治疗进展[J].四川医学,2005,26(8):896-897. 被引量:3
-
4张明,郭慕依,张秀荣,金惠铭.肾小球系膜增生机制的免疫组化研究[J].中华肾脏病杂志,1995,11(4):208-211. 被引量:16
-
5李晓曦.永久性甲状旁腺功能减退的治疗[J].国际外科学杂志,2013,40(1):8-10. 被引量:2
-
6江丽汗,白皓.甲状旁腺素与慢性肾功能衰竭[J].内蒙古中医药,2010,29(12):117-118. 被引量:1
-
7合并急性肾衰并需进行肾脏替代治疗的重症患者是否需使用EPO[J].中华医学信息导报,2006,21(1):11-11.
-
8张晓萍,林清,王美水.白藜芦醇对瘢痕疙瘩成纤维细胞自噬的影响[J].中华实验外科杂志,2016,33(12):2685-2687. 被引量:1
-
9谭焕源.慢性肾功能衰竭继发性甲状旁腺功能亢进的治疗进展[J].中国老年保健医学,2013,11(3):74-76. 被引量:6
-
10别嘌醇可延缓肾脏疾病进程[J].中华医学信息导报,2006,21(2):9-9.